EC
AKBA icon

EntryPoint Capital’s Akebia Therapeutics AKBA Stock Holding History

EntryPoint Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Buy
201,749
+74,248
+58% +$102K 0.08% 496
2025
Q4 		$205K Buy
127,501
+83,050
+187% +$174K 0.08% 544
2025
Q3 		$121K Buy
44,451
+3,455
+8% +$11.5K 0.05% 610
2025
Q2 		$149K Buy
+40,996
New +$113K 0.07% 534
2024
Q2 		– Sell
-10,590
Closed -$19.4K – 850
2024
Q1 		$19.4K Buy
+10,590
New +$16.9K 0.02% 1101

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EntryPoint Capital's AKBA Position: Q1 2026 in Review

EntryPoint Capital increased its Akebia Therapeutics (AKBA) stake by 58% in Q1 2026, buying an estimated $102K and bringing the position to 201,749 shares worth $280K. The position accounts for 0.08% of the portfolio, ranked #496.

EntryPoint Capital first reported a position in AKBA in Q1 2024 and has held it in 5 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • EntryPoint Capital held 201,749 shares of Akebia Therapeutics worth $280K as of Q1 2026.
  • EntryPoint Capital bought 74,248 Akebia Therapeutics shares in Q1 2026, an estimated $102K.
  • Akebia Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q1 2026, its #496 holding.
  • EntryPoint Capital first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.